IGC Pharma, Inc. IGC
IGC Pharma, Inc. (NYSE: IGC) is a CNS/neurology/psychiatry drug developer. Its lead program, IGC-AD1, is in Phase 2 for Agitation in Alzheimer's dementia. Its next catalyst on record is IGC-AD1: Final participant dosing expected to conclude (November 2026).
Upcoming catalysts
- November 2026IGC-AD1 — Final participant dosing expected to conclude
Following the protocol-defined six-week treatment period, final participant dosing is expected to conclude mid-November 2026, after which the Company expects to proceed with database lock, unblinding, and topline analysis.
Next further out: IGC-AD1 — Topline results announcement (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IGC-AD1 | Agitation in Alzheimer's dementia | small molecule | Phase 2 |
| TGR-63 | Alzheimer's disease mechanisms | unclear | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.